The term "mycoplasma" refers to a genus of bacteria usually found in cell culture. These bacteria lack a cell wall more correctly known as mollicutes, making them resistant to widely used antibiotics, such as penicillin.
As per Market Research Future (MRFR) analysis, the global mycoplasma testing market is estimated to expand significantly over the forecast period. The global mycoplasma testing market held a market value of USD 514 million in 2017 and is anticipated to grow at a CAGR of 11.6% from 2018 to 2023 (forecast period).
Mycoplasma is quickly transmitted by droplets during cell culture and can persist in dry form for months. Contamination of mycoplasma is challenging to see with a microscope and requires complex tests to be identified. Contamination may have a profound impact on experimental work. Depending on the species present, mycoplasma organisms may affect cell growth, metabolism, tumorigenicity, and the response to chemotherapy.
Increasing research and development efforts have resulted in higher revenues for the global market for mycoplasma testing. Some of the major players on the market are also investing a tremendous amount of money in this market to come up with advanced and better solutions to deliver to their customers. In addition, growing expenditure in the healthcare sector and increasing research in life science are expected to generate lucrative growth opportunities in this market. The introduction of emerging technology for the production and discovery of drugs would also support the industry's growth in the coming years. However, the availability of alternative traditional methods may hamper market growth over the forecast period.
The global market for mycoplasma testing has been segmented into product, technique, application, and end-user.
Based on the product, the global market for mycoplasma testing segmented into kits reagents, instruments, and services. The kits reagents segment is expected to account for the largest share segment of the market in 2017.
Based on technique, the global market for mycoplasma testing segmented into kits DNA Stain, Enzyme-based, PCR, ELISA, Direct Assay, Indirect Assay, Others.
Based on application, the global market for mycoplasma testing segmented into kits cell line and cell therapy testing, virus testing, row material testing, lot release testing, and others.
Based on end-user, the global market for mycoplasma testing segmented into kits pharmaceutical and biological manufacturing, contract research organizations, cell banks, and others.
Regionally, the global market for mycoplasma testing segmented into the Americas, Europe, Asia Pacific, and the Middle East Africa.
Geographically, the Americas are expected to dominate the global market for mycoplasma testing due to a well-established players and rising RD costs.
Europe is set to retain the second-largest position in the global market for mycoplasma testing. The growth of the market in this area is due to the development of the pharmaceutical and medical device industries.
The market for mycoplasma testing in the Asia Pacific region consists of countries like China, Japan, the Republic of Korea, India, Australia, and the rest of Asia Pacific. The Asia Pacific region is projected to be the fastest-growing region due to the increasing adoption of these products.
Some of the significant participants in the global mycoplasma testing market are Charles River Laboratories, Inc., Merck KGaA, Lonza Group Ltd, Roche Diagnostics, SGS S.A., American Type Culture Collection, Invivogen, Wuxi Apptec, Thermo Fisher Scientific Inc., Promocell GmbH.